Project Grant HT94252411119
Award Date
9/30/24
Completion Date
9/29/26
Dollars Obligated
$585K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Kenya
Similar Awards
This federal Project Grant award of $738,775.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), will fund the "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA" research initiative. The primary awardee, the University of Pretoria in South Africa, will conduct advanced biomedical research focused on transforming healthcare for military...
This federal Project Grant award of $3,580,840.00, titled "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA", was awarded on September 30, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public,...
This federal Project Grant award of $1,839,317.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Illinois. The grant aims to evaluate the interrelated roles of environmental exposures and multi-omic factors on high-risk prostate cancer among men of African ancestry. Key components include: Establishing a translational study site at the University of Calabar Teaching Hospital in Nigeria to recruit 120...
The federal Project Grant award of $582,309.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research efforts led by the University of Cape Town (UCT) in South Africa. The funding will be used by UCT, a leading research institution in Africa, to conduct advanced biomedical research focused on "TANDEM 2: CLOSING THE GAP TO INTERVENTIONS FOR TAND" over the period of July 15, 2024 to July 14, 2027. The research...
The Defense Health Agency awarded a $1,346,633 Project Grant to the George Washington University under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research titled "A PRIMARY ROLE FOR THE CIRCULATORY MICROENVIRONMENT IN AFRICAN AMERICAN PROSTATE CANCER DISPARITIES?" from May 15, 2023 to May 14, 2026. As the prime awardee, George Washington University will investigate medical solutions for prostate cancer disparities affecting African...
This federal Project Grant award, valued at $1,235,845.00 and awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The project, with a performance period from August 15, 2025 to August 14, 2028, will leverage data science methods to transform healthcare for military service members and the broader public. The...
This Project Grant award of $231,009.44 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) supports research at the University of Adelaide in Australia to understand heterogeneity and improve the precision of prostate cancer clinical outcomes. The 3-year project, which runs from September 1, 2023 to August 31, 2026, aims to advance scientific understanding and develop new treatments related to prostate cancer, a key health condition affecting...
This federal Project Grant award of $1,525,292 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a research project led by Oregon Health & Science University (OHSU) to characterize the progression of prostate cancer through integrated analysis of single-cell data. The project, which commenced on September 30, 2024 and is scheduled for completion by September 29, 2027, aims to advance the understanding of prostate cancer biology and...
This $1,927,373 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports the development of targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency. The award was granted to the Fred Hutchinson Cancer Center, a prominent non-profit medical research organization located in Seattle, Washington, on February 15, 2025, with an ultimate completion date of February...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...